Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $49 from $45 and keeps a Buy rating on the shares post the Q2 report. The firm increased estimates to reflect the company’s South Korea and Canada licensing agreements.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz Therapeutics Prepares for LNZ100 Launch
- LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval
- Lenz Therapeutics reports Q2 EPS (53c), consensus (54c)
- Lenz announces CORXEL submitted NDA for LNZ100 in China
- Lenz Therapeutics price target raised to $48 from $38 at H.C. Wainwright